- Home
- ECX vs ERAS Comparison
ECX vs ERAS Comparison
Compare ECX & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECX
- ERAS
- Stock Information
- Founded
- ECX 2017
- ERAS 2018
- Country
- ECX China
- ERAS United States
- Employees
- ECX N/A
- ERAS N/A
- Industry
- ECX EDP Services
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- ECX Technology
- ERAS Health Care
- Exchange
- ECX Nasdaq
- ERAS Nasdaq
- Market Cap
- ECX 600.6M
- ERAS 484.4M
- IPO Year
- ECX N/A
- ERAS 2021
- Fundamental
- Price
- ECX $1.67
- ERAS $1.60
- Analyst Decision
- ECX Strong Buy
- ERAS Strong Buy
- Analyst Count
- ECX 1
- ERAS 6
- Target Price
- ECX $3.20
- ERAS $4.50
- AVG Volume (30 Days)
- ECX 3.3M
- ERAS 749.3K
- Earning Date
- ECX 08-26-2025
- ERAS 08-12-2025
- Dividend Yield
- ECX N/A
- ERAS N/A
- EPS Growth
- ECX N/A
- ERAS N/A
- EPS
- ECX N/A
- ERAS N/A
- Revenue
- ECX $805,604,079.00
- ERAS N/A
- Revenue This Year
- ECX $26.72
- ERAS N/A
- Revenue Next Year
- ECX $30.72
- ERAS N/A
- P/E Ratio
- ECX N/A
- ERAS N/A
- Revenue Growth
- ECX 19.98
- ERAS N/A
- 52 Week Low
- ECX $0.76
- ERAS $1.01
- 52 Week High
- ECX $3.25
- ERAS $3.31
- Technical
- Relative Strength Index (RSI)
- ECX 51.51
- ERAS 55.28
- Support Level
- ECX $1.58
- ERAS $1.44
- Resistance Level
- ECX $1.74
- ERAS $1.68
- Average True Range (ATR)
- ECX 0.10
- ERAS 0.11
- MACD
- ECX 0.02
- ERAS 0.00
- Stochastic Oscillator
- ECX 69.23
- ERAS 67.69
About ECX ECARX Holdings Inc. Ordinary shares
ECARX Holdings Inc is engaged in the sales of system-on-chip core modules, automotive computing platform products, and software stacks as well as the provision of research and development services in the People's Republic of China. The company's core products include infotainment head units, digital cockpits, vehicle chip-set solutions, a core operating system, and an integrated software stack. Beyond this, ECARX is developing a full-stack automotive computing platform. It is engaged in automotive intelligence and networking.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.